LYKALABSNSELyka Labs Limited· PharmaceuticalsLowNeutral
Announced Fri, 10 Apr · 15:21 IST

Lyka Labs Limited has Submitted to the Exchange a copy of Disclosure under Regulation 31(4) of the Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011

Ownership Changes View source PDF

LYKALABS · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve 14 horizons · vs prior close
-0.3%1-day move
₹58.10
prior close
₹58.45
base price
In-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
-0.7-0.3-2.1-0.7+3.2-0.1+2.4-1.0+10.2+23.9+23.5
Up moveDown movePending
AI summary

Lyka Labs Limited's promoters and persons acting in concert (PAC) have submitted a disclosure confirming that during FY 2025-26, no equity shares were pledged. As of 31st March 2026, the total pledged quantity stands at NIL. The promoters also declared that no new encumbrances were created during the financial year beyond what was already disclosed. This is a routine regulatory filing under SEBI takeover regulations requiring disclosure of promoter share pledges.

Likely market impact

A nil pledge declaration is generally viewed positively by investors as it indicates promoters have not leveraged their shareholding for loans, reducing risk of forced selling. The stock does not face immediate pledge-related pressure.